Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

NCT02422498 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02422498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02422498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 14, 2015
Completion date
April 14, 2028
Enrollment
49 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

locally recurrent/metastatic triple negative breast cancer